HAYWARD, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today provided a business update and reported financial results for the second quarter ended June 30, 2017.
Recent Developments and Business Highlights:
Sollpura™ (liprotamase) for the treatment of Exocrine Pancreatic Insufficiency (“EPI”)
Phase 3 RESULT study began screening patients in the U.S. and Europe
